Skip to main content

Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies

Buy Article:

$43.00 plus tax (Refund Policy)

Frye MA, Yatham L, Ketter TA, Goldberg J, Suppes T, Calabrese JR, Bowden CL, Bourne E, Bahn RS, Adams B. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Objective: 

To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: 

Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: 

Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: 

Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: bipolar; depression; lithium; thyroid-stimulating hormone

Document Type: Research Article

Affiliations: 1: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA 2: Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada 3: Department of Psychiatry, Stanford University, Palo Alto CA, USA 4: Silver Hill Hospital, New Canaan, CT, USA 5: Department of Psychiatry, Stanford University, Palo Alto VA Medical Center, Palo Alto, CA, USA 6: Department of Psychiatry, Case Western University, Cleveland, OH, USA 7: Department of Psychiatry, University of Texas, San Antonio, TX, USA 8: GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC, USA 9: Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

Publication date: 2009-07-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more